News | Heart Valve Technology | April 29, 2025

STS Debuts Risk Calculator for Ascending Aorta and Aortic Root Surgery

Developed using data from more than 67,000 patients, the new calculator provides individualized operative risk estimates for four key procedural groups.

STS Debuts Risk Calculator for Ascending Aorta and Aortic Root Surgery

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for patients undergoing ascending aorta and aortic root surgery, with or without concomitant aortic valve replacement (AVR). This first-of-its-kind tool represents a major step forward in risk stratification and personalized surgical planning for complex aortic operations.

Developed using data from more than 67,000 adult ascending aorta and aortic root surgeries submitted to the STS Adult Cardiac Surgery Database (ACSD) between July 2017 and December 2024, the new calculator provides individualized operative risk estimates for four key procedural groups:

1.    Bentall procedures involving AVR
2.    Ascending aorta plus AVR
3.    Valve-sparing root replacement
4.    Isolated ascending aorta surgery

The risk calculator supports more accurate assessments of expected outcomes, including mortality and major morbidity, based on real-world data collected through STS’s expanded aorta surgery module. 

“This risk calculator fills a critical gap for cardiothoracic surgeons treating complex aortic pathology,” said STS President Joseph F. Sabik III, MD. “It empowers surgeons to have more transparent, productive conversations with patients and families about surgical risks and benefits, leading to better-informed decision making.”

Aortic operations accounted for nearly 11.2% of all major cardiac surgeries in the United States in 2024, up from 8.3% in 2018—a trend that underscores the growing need for tailored decision-support tools in this area. Until now, surgeons lacked a validated method to assess operative risk for ascending aorta and aortic root procedures at the bedside.

In addition to its clinical utility, the mobile-friendly calculator is expected to support the design and evaluation of new clinical trials and comparative studies, particularly those exploring the outcomes of traditional surgery versus less invasive procedures.

"This new tool is not only a clinical asset, but also a catalyst for research,” added Dr. Sabik. “It will support the design and evaluation of new clinical trials and studies, especially those comparing open aortic surgery to less invasive alternatives, a critical and growing area of interest in cardiovascular care.”

The risk models implemented in this tool are based on the study, “Development of a Novel Society of Thoracic Surgeons Aortic Surgery Mortality and Morbidity Risk Model,” published in The Annals of Thoracic Surgery. The study describes the methodology and validation behind the risk stratification framework.

The ACSD is part of the STS National Database, one of the largest and most comprehensive clinical registries in health care. With nearly 10 million cardiothoracic procedures submitted by more than 4,300 surgeons, the STS Database captures over 95% of adult and congenital cardiac surgery procedures performed in the United States, along with a majority of lung and esophageal cancer surgeries. As a result, the STS Database provides true national benchmarks for clinical outcomes in cardiothoracic surgery.

The Ascending Aorta and Aortic Root Surgery Risk Calculator is the latest in a series of enhancements to the STS National Database designed to meet the day-to-day needs of surgeons and cardiothoracic care teams. It joins a trusted portfolio of STS adult cardiac surgery risk calculators that provide individualized risk assessments for procedures such as isolated tricuspid valve repair and replacement; surgical aortic valve replacement (SAVR) after prior transcatheter aortic valve replacement (TAVR); and multi-valve surgery with or without coronary artery bypass grafting (CABG). These tools predict outcomes such as mortality, stroke, and length of hospital stay.

This launch reinforces STS’s commitment to delivering high-impact resources that support surgeon excellence and innovative cardiovascular research. 


Related Content

News | Heart Valve Technology

Dec. 26, 2025 — Edwards Lifesciences has announced the company’s SAPIEN M3 mitral valve replacement system, a ...

Home December 24, 2025
Home
News | Heart Valve Technology

Nov. 17, 2025 — Royal Philips has introduced DeviceGuide, an AI-powered device tracking* solution that assists ...

Home November 17, 2025
Home
News | Heart Valve Technology | Cedars-Sinai Medical Center

Oct. 28, 2025 — People who underwent a minimally invasive procedure to have their heart’s aortic valve replaced had ...

Home October 29, 2025
Home
News | Heart Valve Technology

Aug. 28, 2025 — Medtronic plc has announced it received U.S. Food and Drug Administration (FDA) approval for the ...

Home August 29, 2025
Home
News | Heart Valve Technology

Aug. 18, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home August 19, 2025
Home
News | Heart Valve Technology

Aug. 4, 2025 — Corcym announced that its Perceval Plus sutureless aortic heart valve was used in a first-ever robotic ...

Home August 05, 2025
Home
News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
Subscribe Now